The pharmaceutical company "http://www.gsk.com/" GlaxoSmithKline (GSK) has selected the Oncology Service of Vall d’Hebron University Hospital as one of the six international renowned members of the Oncology Clinical and Translational Consortium (OCTC). The new network will provide collaborations in oncology research focused towards the development of the next generation of novel oncology therapeutics.The participants of the consortium will have access to GSK’s studies in early stages of the clinical development, as well as to translational and preclinical studies. The centers will also design and execute research programs in a focused and expeditious way, allowing the development of new diagnostic tools and medicines to better treat cancer patients.The other five centers of the study are Gustave Roussy (France), the University of Texas MD Anderson Cancer Center (USA), the Memorian Sloan-Kettering Cancer Center (USA), el Netherlands Cancer Institute (Netherlands) and the Princess Margaret Cancer Centre University Health Network (Canada). All of them, together with Vall d’Hebron, will collaborate on processes to ensure the highest quality standards for collection of biological samples, as well as conduct of biomarker and clinical research.